Journey Medical Corp (DERM) Form 8-K — May 13, 2026
Journey Medical Corporation reported total revenues of $16.0 million for the first quarter of 2026, a 21% increase from $13.1 million in the first quarter of 2025. This growth was primarily driven by Emrosi® revenues, which increased to $6.3 million from $2.1 million in the same period last year. The company's gross margin decreased to 61.0% for the first quarter of 2026, from 63.5% in the first quarter of 2025, due to a $1.3 million non-recurring non-cash charge against cost of goods related to the 2021 Qbrexza® asset acquisition.
Key figures
- Eps Beat
- 0
- Revenue
- 16000000
- Total Debt
- 60703000
- Debt Amount
- 0
- Revenue Yoy
- 21
- Total Assets
- 91534000
- Cash Position
- 27219000
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 27305028
- Emrosi revenue
- 6300000
- Adjusted ebitda
- 623000
- Emrosi prescriptions
- 29968
- Adjusted ebitda per share
- 0.02
Price after filing
Close on the filing date to close N calendar days later (from $5.19). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.